Propanc Biopharma Files 8-K: Material Agreement, Debt, Equity Sales
Ticker: PPCB · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Mar 11, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $50,000, $46,875, $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, equity-sale
TL;DR
Propanc Biopharma inks new deal, takes on debt, and sells stock.
AI Summary
Propanc Biopharma, Inc. announced on March 5, 2024, that it entered into a material definitive agreement. The company also reported the creation of a direct financial obligation and unregistered sales of equity securities. The filing details financial statements and exhibits related to these events.
Why It Matters
This 8-K filing indicates significant financial and contractual activity for Propanc Biopharma, including new obligations and equity transactions, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, suggesting potential financial risks and dilution for shareholders.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- March 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 000-54878 (filing_id) — SEC File Number
- 33-0662986 (tax_id) — IRS Employer Identification Number
- 302 , 6 Butler Street Camberwell , VIC , 3124 Australia (address) — Business Address
FAQ
What type of material definitive agreement did Propanc Biopharma, Inc. enter into?
The filing states that Propanc Biopharma, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in the excerpt.
What is the nature of the direct financial obligation created by Propanc Biopharma, Inc.?
The filing indicates the creation of a direct financial obligation, but the specific terms and amount of this obligation are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 5, 2024.
What is the company's state of incorporation and SEC file number?
Propanc Biopharma, Inc. is incorporated in Delaware and its SEC file number is 000-54878.
Does the filing mention any unregistered sales of equity securities?
Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item information, indicating such sales have occurred.
Filing Stats: 1,075 words · 4 min read · ~4 pages · Grade level 12.6 · Accepted 2024-03-11 15:15:04
Key Financial Figures
- $50,000 — ny in the aggregate principal amount of $50,000 (the "Note"), for a purchase price of $
- $46,875 — 0 (the "Note"), for a purchase price of $46,875. The Company intends to use the net pro
- $0.001 — common stock of the Company, par value $0.001 per share (the "Common Stock"), at the
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex4-1.htm (EX-4.1) — 157KB
- ex10-1.htm (EX-10.1) — 150KB
- 0001493152-24-009536.txt ( ) — 589KB
- ppcb-20240305.xsd (EX-101.SCH) — 3KB
- ppcb-20240305_lab.xml (EX-101.LAB) — 33KB
- ppcb-20240305_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 11, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer